Background: Results from the recent SPRINT trial demonstrate lower rates of fatal and non-fatal major cardiovascular events and all-cause mortality in non-diabetics at high cardiovascular risk with intensive versus standard treatment, i.e., less than 120 versus less than 140 mmHg systolic, respectively. However, the long-term outcomes remain unknown.Methods: A validated state-transition model with multivariate risk [...]

Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]

Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]

Background: Clostridioides difficile infection (CDI) is the most common health care–associated infection in the United States and has serious clinical consequences with limited data on economic impact on US hospitals. The objective of this study was to quantify the cost of hospitalizations, readmissions, and expected reimbursement for each all-cause and CDI-related hospitalization during 12 months [...]

Background: Growth of physician owned hospitals (POH) in the United States has been restricted since the 2010 passage of the Affordable Care Act (ACA). Federal policy makers wanted to restrict POH, due to concerns that POH may cherry pick healthier patients, treat fewer Medicaid patients, and have higher service utilization. Data has shown an unclear [...]